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A depressive disorder is a disease characterized by a heterogenous background. The important processes observed and diagnosed 
in depressed patients indicate that the etiology of depression may include disturbances in thyroid hormone (TH) levels and the 
occurrence of immune‑inflammatory activation. Type 1 (DIO1) and type 3 (DIO3) iodothyronine deiodinases are the enzymes 
which determine the peripheral and tissue levels of TH, but also interfere with immunological cells and inflammatory processes. 
We aimed to investigate the levels of DIO1 and DIO3 in the patients suffering from recurrent depressive disorders (rDD). Data 
collected from 91 rDD patients and 105 healthy controls were analyzed. The diagnoses were made based on the ICD‑10 criteria 
(F33.0–F33.8). The expression levels of DIO1 and DIO3 were estimated using the polymerase chain reaction method and the 
enzyme‑linked immunosorbent assay (ELISA). The expression of DIO1 on mRNA/protein levels in the rDD patients was reduced 
in comparison to the control subjects, while the expression of DIO3 was higher in the patients suffering from depression. No 
significant relationship was found between the investigated DIOs and other clinical parameters. Our results indicate and suggest 
a  role of DIO1 and DIO3‑related pathways in the pathophysiology of depression. The results represent a  promising way to 
investigate the biological markers of depression.
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INTRODUCTION
A depressive disorder is a multifactorial disease the 
mechanism of which has not been fully examined so far. 
Certain observations indicate that disturbances in 
thyroid hormone (TH) levels, including a decrease or an 
increase outside normal ranges, are characteristic for 
the patients suffering from depression (Baumgartner 
et al. 1988, Eker et al. 2008, Linnoila et al. 1982). Other 
processes found in unipolar depression in the plasma 
and cerebrospinal fluid (CSF), and in postmortem stud‑
ies (Raedler 2011), include immune activation as well 
as increased concentration of pro‑inflammatory cyto‑
kines and inflammation‑related molecules. Moreover, 
increased levels and activity of monocytes and macro‑
phages are observed in depression (Maes et al. 2009). Se‑
lected results also indicate a role of lipopolysaccharides 
(LPS) and a bacterial or viral infection in the pathophys‑
iology of the said disease (Maes et al. 2008). 
Thyroid hormones are widely distributed in the 
brain and are significant for its proper functioning. 
Moreover, the limbic system, in which TH receptors 
play a particularly important role, takes part in the 
pathogenesis of depression (Bauer et al. 2008). What 
is more, TH and TH synthesis‑related molecules are 
now confirmed and strongly investigated as immune 
response and inflammation modulators (de Vito et al. 
2012). 
The synthesis and levels of TH are regulated by iodo‑
thyronine deiodinases type I (DIO1), type II (DIO2) and type 
III (DIO3), which remove specific iodine moieties from T4 
or other iodothyronines. Under normal conditions, most 
of circulating T3 is produced by DIO1 and its expression is 
observed mainly in the thyroid and kidneys. DIO1 is also 
expressed in lymphocytes; it has been confirmed that its 
expression is influenced by pro‑inflammatory cytokines 
(Köhrle 1999). The enzyme involved in reductive deiodin‑
ation is DIO3 – it eliminates T4 by way of transformation 
to reverse T3 (rT3) and diiodothyronine (T2). Under nor‑
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mal conditions, D3 is expressed in the majority of organs, 
including the brain – mainly neurons of the hippocampus 
(Bianco and Kim 2006, Köhrle 1999). On the other hand, 
aberrant expression of DIO3 is observed in pathological 
conditions (Richard et al. 1998). For example, high expres‑
sion of DIO3 is found in activated monocytes and macro‑
phages, which supports the hypothesis that DIO3 plays 
a role in chemical and bacterial inflammations (Boelen 
et al. 2008, Boelen et al. 2009). In addition, the protective 
role of DIO3 against inflammation is suggested (Boelen et 
al. 2009). To shortly sum up, deiodinases – including DIO1 
and DIO3 – interfere with immuno‑inflammatory process‑
es and influence the expression and release of inflamma‑
tory cytokines (Bartalena et al. 1998). 
The exact expression levels and involvement of DIO1 
and DIO3 in depression have not been investigated in the 
patients diagnosed with a depressive disorder/healthy 
controls yet, and are rather unknown. To the best of our 
knowledge, only one recently published study has investi‑
gated DIO3 gene deficiency on an animal model (Stohn et 
al. 2016). Considering the fact that the DIO1 and DIO3 en‑
zymes determine TH levels, are involved in other processes 
observed in depression, and may directly interfere with the 
immune‑inflammatory mechanisms, we aimed to investi‑
gate the expression of DIO1 and DIO3 on mRNA and protein 
levels in the patients suffering from recurrent depressive 
disorders (rDD). 
MATERIALS AND METHODS
Subjects 
196 individuals, aged 18–64 (M=37.41 years, 
SD=±13.74), were engaged to participate in the study, in‑
cluding patients diagnosed with rDD (n=91) and control 
subjects (n=105). The number of depressive episodes 
and hospitalizations, and the duration of the disease, 
were recorded for everyone. The diagnosis of rDD was 
made based on the ICD‑10 criteria (F33.0–F33.8). A med‑
ical history was obtained in all cases and assessed using 
the standardized Composite International Diagnostic 
Interview (CIDI) form (Patten 1997). The Hamilton De‑
pression Rating Scale (HDRS) was applied to estimate 
the severity of depressive symptoms. The group of con‑
trol subjects comprised selected healthy community 
representatives invited to take part in the study based 
on the absence of diagnostic criteria of the psychiatric 
CIDI interview. A description of the samples is present‑
ed in Table I. We excluded from the study both patients 
and controls with other psychiatric axis I and II disor‑
ders. The exclusion criteria were as follows: (auto)im‑
mune‑inflammatory diseases and thyroid diseases. All 
the patients were native inhabitants of central Poland, 
and were unrelated to one another. All the procedures 
were reviewed and approved by the Local Bioethics 
Table I. Demographic characteristics of the group with rDD in comparison to controls, and data concerning the course of the disease
Characteristics rDD (n=91) controls (n=105)
n % M (±SD) n % M (±SD)
Sex
Female 53 58.24 – 69 65.71 –
Male 38 41,76 – 36 34.29 –
Age in years – – 47.24  (11.82) – –
28.89  
(8.69)
Education level
Primary 8 8.79
Vocational 18 19.78 – – – –
Secondary 46 50.55 – 57 54.29 –
College/University 19 20.88 – 48 45.71 –
rDD
Disease duration in years – – 6.43  (7.72) – – –
Number of depression 
episodes totalled – –
4.44  
(5.32) – – –
Number of hospitalization 2.09 (1.61)
HDRS baseline 22.79 (6.14)
HDRS final 6.88 (4.36)
rDD – recurrent depressive disorders; HDRS – Hamilton Depression rating Scale; n – number of samples; % – percentage; M – mean; ±SD – standard deviation.
4_974_Galecka_v4.indd   226 19/10/17   23:27
Deiodinase in depression 227Acta Neurobiol Exp 2017, 77: 225–235
Committee. Written informed consent was obtained 
from all the participants of the study. 
RNA isolation and RT‑PCR
Total RNA was extracted from the patients’ blood sam‑
ples using TRIZOL (Invitrogen Life Technologies, Carlsbad, 
CA, USA), an RNA extraction reagent, according to the 
standard acid‑guanidinium‑phenol‑chlorophorm meth‑
od (Chomczyński et al. 1987). The absorbance of isolated 
RNA was measured using a spectrophotometer (Picodrop, 
Hinxton, UK) at λ=260 nm to determine total RNA concen‑
tration. 
The quality of total RNA was checked and verified with 
Agilent RNA 6000 Nano Kit (Agilent Technologies, Santa 
Clara, CA, USA) in accordance with the manufacturer’s rec‑
ommendations, using 2100 Bioanalyzer (Agilent Technol‑
ogies, Santa Clara, CA, USA). Complementary DNA (cDNA) 
was transcribed from total RNA using TaqMan® RNA Re‑
verse Transcription Kit (Applied Biosystems Foster City, 
CA, USA) based on the manufacturer’s recommendations. 
The samples were incubated (at 16°C for 30 minutes and at 
42°C for 30 minutes) in a thermocycler (Biometra, Gottin‑
gen, Germany). Reverse transcriptase was inactivated (at 
85°C for 5 minutes) and the obtained cDNA was stored at 
a temperature of ‑20°C.
Real‑Time PCR reaction was conducted using TaqMan® 
Universal PCR Master Mix, No UNG (Applied Biosys‑
tems, Foster City, CA, USA), according to the protocol 
provided by the manufacturer, using Hs00174944_m1, 
Hs00956431_s1, Hs04194366_g1 probes delivered by Ap‑
plied Biosystems, specific for DIO1, DIO3 and RPL13A, re‑
spectively. The Ct comparative method was applied to 
calculate expression of mRNA genes. The level of DIO1 
and DIO3 gene expression was normalized in relation to 
the RPL13A reference gene.
Each target probe was amplified in a separate 
96‑well plate. All the samples were incubated at 50°C 
for 2 minutes and at 95°C for 10 minutes, and then cy‑
cled at 95°C for 30 seconds, at 60°C for 30 seconds and 
at 72°C for 1 minute; 40 cycles were performed in total. 
Fluorescence emission data were captured and mRNA 
levels were quantified using the critical threshold (Ct) 
value. Analyses were conducted in ABI Prism 7000 (SDS 
Software, Applied Biosystems). Controls without RT 
and with no template cDNA were carried out with each 
assay. The threshold cycle (Ct) was calculated for each 
sample. RT‑PCR amplification of the DIO1 and DIO3 gene 
was compared to that of RPL13A, a house‑keeping refer‑
ence gene, and ΔCt was determined (ΔCt=Ctgene‑CtR‑
PL13A) in each patient and control subject. The results 
were analyzed according to the 2‑Δct method (Schmitt‑
gen and Livak 2008)
Determination of protein concentration with 
enzyme‑linked immunosorbent assay (ELISA)
Human enzyme‑linked immunosorbent assays were 
used to detect DIO and DIO3 levels in serum. The se‑
rum was separated from peripheral blood using clot ac‑
tivating tubes. Next, the samples were allowed to clot 
for 30 minutes and then centrifuged for 15 minutes at 
approximately 1000x g. After the centrifugation, the 
serum was removed and stored aliquot at ‑80°C. DIO1 
and DIO3 levels were measured using commercially 
available Human DIO1 ELISA Kit (MyBioSource, San Di‑
ego, CA, USA) and Human DIO3 ELISA Kit (MyBioSource, 
San Diego, CA, USA). The results were calculated ac‑
cording to the instructions and protocols provided 
by the manufacturers. The absorbance of the samples 
was measured using Multiskan Ascent Microplate Pho‑
tometer (Thermo Labsystems, Waltham, MA, USA) at 
λ=450 nm. Analytical curves for the analyzed proteins 
were worked out to determine protein concentration. 
Serum DIO1 and DIO3 levels were presented as U/L. The 
detection range kit for deiodinase type 1 produced by 
MyBioSource totals from 3.12 U/L to 100 U/L. The de‑
tection range kit for deiodinase type 3 produced by My‑
BioSource is from 0.625 U/L to 20 U/L. Both Intra‑as‑
say CV(%) and Inter‑assay CV(%) is less than 15 [CV(%) 
=SD/mean x100].
Statistical analysis
All data analyses were performed using Statistica 
(version 12.0). A statistical analysis of the collected 
material included calculation of both descriptive and 
inferential statistics. The results were presented as 
percentages (%) or means (M) with standard deviations 
(±SD). The chi‑square test and Mann‑Whitney U‑ test 
were used to compare demographic variables (gender 
and age) between the patients and the controls. The 
comparison of DIO1 and DIO3 expression levels between 
the subjects with rDD and the controls was performed 
using non‑parametric Mann‑Whitney U‑test. The Pear‑
son correlation was calculated to evaluate the relation‑
ships between the analyzed mRNA/protein levels and 
the features of depression. Statistical significance was 
defined as P<0.05 for all the analyses.
RESULTS
No significant differences were found between the 
rDD patients and the controls with respect to gender 
(χ2=1.16, P=0.28). The groups were gender‑matched but 
varied significantly with respect to age distribution 
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(Z=8.65, P<0.001). There were significant differenc‑
es in DIO1 and DIO3 expression between the patients 
and the controls on both the mRNA and protein level 
(Mann‑Whitney U‑test P<0.001). The obtained results 
indicated that DIO1 expression levels were significantly 
lower in the patients diagnosed with rDD in compari‑
son to the controls, while DIO3 expression was signifi‑
cantly higher in the individuals affected by depression. 
Detailed results can be found in Table II.
The significant differences on both the mRNA and 
protein level were also observed between the group 
of males with rDD and healthy males, and between fe‑
Table II. Expression on the protein level and on the level of mRNA for DIO1 and DIO3 in the examined group
Variable rDD n=91; M (±SD) Controls n=105; M (±SD) Mann – Whitney U‑test (P)
DIO1 protein (U/L) 20.03  (5.14)
22.72  
(4.46) = 0,000212
DIO1 mRNA ((2‑∆ct) 0.07  (0.02)
0.08  
(0.015) = 0,000159
DIO3 protein (U/L) 16.70  (3.90)
13.36  
(6.35) = 0,000001
DIO3 mRNA ((2‑∆ct) 0.06  (0.014)
0.046  
(0.02) = 0,000001
DIO1 – deiodinase type 1; DIO3 – deiodinase type 3; n – number of subjects; rDD – recurrent depressive disorders;  M – mean; SD – standard deviation; P – level of statistical 
significance.
Fig. 1. Correlation between Hamilton Depression Rating Scale (HDRS) baseline and deiodinase type 1 (DIO1) protein levels in patients with recurrent 
depressive disorder.
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males with rDD and healthy female subjects on both the 
mRNA and protein levels. Detailed results are present‑
ed in Table III. 
No differences were found between rDD males and 
rDD females as well as between healthy control males 
and females (Mann‑Whitney U‑test P > 0.05). Pearson’s 
statistics show no correlation between DIO1 and DIO3 
expression on mRNA/protein levels, and clinical vari‑
ables, in rDD patients, except for baseline HDRS for DIO1 
protein (P<0.05; Fig. 1).
Table III. Expression on the protein level and on the level of mRNA for DIO1 and DIO3 in females and males with rDD and controls
Variable rDD femalesn=53
control females
n=69
Mann – Whitney 
U‑test
rDD males
n=38
control males
n=36
Mann – Whitney 
U‑test
M (±SD) M (±SD) p M (±SD) M (±SD) P
DIO1 protein (U/L) 20.09  (5.56)
22.72  
(4.54) 0.0028
19.74  
(5.32)
22,71  
(4,37) 0.0107
DIO1 mRNA
(2‑∆ct)
0.069  
(0.02)
0.079  
(0.016) 0.00098
0.07  
(0.017)
0,079  
(0,014) 0.014
DIO3 protein (U/L) 16.52  (3.38)
13.91  
(6.47) 0.0026
17.57  
(4.5)
12,31  
(6,05) 0.000009
DIO3 mRNA
(2‑∆ct)
0.057  
(0.014)
0.048  
(0.023) 0.0022
0.06  
(0.016)
0,042  
(0,02) 0,000007
DIO1 – deiodinase type 1; DIO3 – deiodinase type 3; n – number of subjects; rDD – recurrent depressive disorders; M – mean; SD – standard deviation; P – level of statistical 
significance.
Fig. 2. Correlation between deiodinase type 1 (DIO1) mRNA and DIO1 protein in patients with recurrent depressive disorder.
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Significant relationships were observed between the 
expression of DIO1 on the mRNA and protein levels, and 
between the DIO3 gene and protein expression in the pa‑
tients as well as the controls (P<0.05; Figs 2, 3, 4, 5). 
DISCUSSION
To our knowledge, this is the first study ever to examine 
the expression of DIO1 and DIO3 on mRNA/protein levels in 
the patients diagnosed with depression.
DIO1 expression in the mononuclear cells of human pe‑
ripheral blood was investigated by Nishikawa et al. (1998) 
in the patients suffering from the Graves’ disease. During 
our investigation, we observed lower levels of DIO1 in de‑
pressed patients when comparing them with healthy sub‑
jects. The results obtained may be used in a discussion 
regarding the role and involvement of the enzyme (mol‑
ecule) mentioned above in the development and course 
of depression. Lower levels of DIO1 can partially explain 
a drop in T3 in depressed patients (Stipcević et al. 2008), 
but also may explain the occurrence of depressive symp‑
toms in hypothyroid patients (Bathla et al. 2016). The data 
obtained support a study conducted by Hickie et al. (1996) 
who suggested that hypothyroidism could play a role in the 
development of some treatment‑resistant depressive dis‑
orders. The authors found that hypothyroidism might have 
an impact on the course of the disorder since the presence 
of lower levels of T3 correlated with treatment‑resistant 
depression. In addition, low DIO1 expression may partially 
be responsible for the presence of depressive symptoms in 
the patients with the non‑thyroidal illness syndrome. The 
syndrome is characterized by low levels of T3 without any 
changes in the thyroid‑stimulating hormone (TSH), and is 
often observed in critically ill patients (de Vries et al. 2015) 
in whom depressive syndrome symptoms are described 
frequently (Davydow et al. 2009). 
Our assumption that lower levels of DIO1 may deter‑
mine low levels of T3 is based on the fact that Nishikawa et 
al. (1998) observed increased mRNA for DIO1 in the patients 
Fig. 3. Correlation between deiodinase type 3 (DIO3) mRNA and DIO3 protein levels in patients with recurrent depressive disorder.
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suffering from the Graves’ disease, which may explain the 
occurrence of hyperthyroiditis during the said disease. 
The level of expression is affected by distinct factors 
and, obviously, lower expression of DIO1 may be caused 
by the action of other molecules. For example, glucocorti‑
coids (GR) and cytokines, such as interleukin‑1 (IL‑1) and 
interleukin‑6 (IL‑6), may reduce the levels of DIO1 (Davies 
et al. 1996, Jakobs et al. 2002, Yu and Koenig 2000, Xu et al. 
2014). This fact is worth mentioning, especially since the 
levels of GR, IL‑1 and IL‑6 are increased in depression, and 
both GR and inflammation could participate in cumula‑
tive damage (Horowitz et al. 2013). Oxidative stress, which 
is also characteristically observed in depression (Czarny 
et al. 2015), is an important factor that may affect and re‑
duce DIO1 levels. Chen et al. (2016) suggest that oxidative 
stress may reduce expression of DIO1 on the mRNA level 
and downregulates the conversion of T4 to T3 through the 
function of DIO1. Similarly to our findings, lower expres‑
sion of DIO1 was also observed in the patients who died 
of cardiovascular collapse and renal failure (Peeters et al. 
2003, Peeters et al. 2005). An inflammation is a patholo‑
gy which often appears in depression and is considered 
a mechanism linking the diseases (Halaris 2013, Oyekçin 
et al. 2012). DIO1 catalyzes deiodination of T4 to produce 
T3 and T2 (Köhrle 1999). The involvement of lower levels 
of DIO1 in depression may be in line with the fact that 
T2 takes part in the mediation of antidepressant effects 
(Markova et al. 2013), while lower levels of DIO1 deter‑
mine lower concentrations of T2. Stimulation of the mi‑
tochondrial function, including respiratory chain (Pinna 
et al. 2003) and mitochondrial biogenesis (de Lange et al. 
2011), is a suggested mechanism by which T2 – alterna‑
tively from other TH – positively influences an antide‑
pressant therapy, which is of great importance, especially 
due to the fact that mitochondrial alterations are impli‑
cated in depression (Marazziti et al. 2011) and antidepres‑
sants stimulate mitochondrial respiration processes (Ig‑
nácio ZM et al. 2015). Moreover, damage to mitochondria 
and mitochondrial DNA as well as a reduced activity of 
respiratory chain enzymes and adenosine triphosphate 
Fig. 4. Correlation between deiodinase type 1 (DIO1) mRNA and DIO1 protein levels in controls.
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production are a new target of antidepressant treatment 
(Maes et al. 2012).
On the other side, the levels of DIO1 in the patients who 
died of brain damage were higher than in the control group 
(Peeters et al. 2005), which needs to be discussed short‑
ly. The main deiodinase in the brain is type 2 deiodinase 
(DIO2) (Köhrle, 1999). In this case one may suggest that the 
higher levels of DIO1 in certain areas of the brain may be 
considered a compensatory mechanism for a drop in DIO2. 
The next objective of our study was to investigate the 
levels of DIO3. We observed that its expression (on the 
mRNA and protein levels) was increased in the patients.
Since immune activation plays a role in depression 
pathomechanism, and deiodinases, including DIO3, are 
known to affect immune‑inflammatory processes, our 
results are in line with other findings. Studies on animal 
models revealed that an inflammation strongly induces 
DIO3 in inflammatory cells (Boelen et al. 2005). Increased 
expression of DIO3 by granulocytes and macrophages was 
found in spinal cord inflammatory lesions in experimen‑
tal autoimmune encephalomyelitis in rats (Boelen et al. 
2009). Similarly, DIO3 was highly expressed in infiltrating 
neutrophilic granulocytes in response to a bacterial in‑
fection (Boelen et al. 2008), while the absence of DIO3 re‑
sulted in the elimination of damaged bacteria (Boelen et 
al. 2009). An observation that LPS induces depressive‑like 
behavior is particularly interesting (Maes et al. 2008). On 
the contrary, according to Boelen et al. (2006), a chronic 
local inflammation results in decreased DIO3 expression 
in hypothalamic paraventricular nucleus. The importance 
of DIO3 and its expression were investigated on an ani‑
mal model (Stohn et al., 2016). The results revealed that 
DIO3‑/‑ mice had increased thyroid hormone levels in the 
brain, which was associated with reduced anxiety and de‑
pression‑like behaviors. The data in this case confirmed 
that the status of the thyroid hormone can be consid‑
ered a determinant of behavior. Taking these results into 
account, another mechanism of respective deiodinase 
should be discussed and investigated considering periph‑
eral and/or brain presence.
Fig. 5. Correlation between deiodinase type 3 (DIO3) mRNA and DIO3 protein levels in controls.
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The data concerning the involvement of DIO1 and 
DIO3 in depressive disorder are sparse. Recently we have 
investigated genetic polymorphism within DIO1 and DIO3 
genes in patients with rDD. No significant relations were 
found between genetic variants and rDD. There were no 
important association between genotypes distribution 
and clinical/demographical variables (Gałecka et al., 
2016). In particular, it should shortly be discussed that 
we observed changes in the levels of both DIO1 and DIO3 
in this study. Polymorphic site within the gene is a sta‑
ble feature. According to our results we can draw a cau‑
tious conclusion that genetic variant within DIO1 and 
DIO3 genes is not a risk factor for the rDD. Nevertheless, 
changes in expression levels of both DIOs observed in 
this study may participate in the disease development 
and/or management.
The presented study may have certain limitations 
related to the fact that mRNA/protein expression lev‑
els can be affected by many factors and mechanisms (i.e. 
transcriptional and post‑transcriptional), depending on 
the type of illness and the presence of other processes, 
and may be also time‑ and cell‑specific. In addition, the 
activation of different signal transduction pathways may 
modulate the levels of expression. For example, seleni‑
um deficiency may reduce DIO1 expression and activity 
by decreasing mRNA (Yang et al. 2006), while sustained 
activation of the mitogen‑activated protein kinase path‑
way or leptin administration may modulate the levels of 
DIO3 expression (Romitti et al. 2016, Kwakkel et al. 2006, 
Boelen et al. 2012). 
It might be valuable to present information about the 
status of thyroid hormones. Nevertheless, we are aware 
of the fact that no such data are demonstrated, which 
limits the study. The information regarding the levels 
of T3 and T4 could obviously expand and improve the 
knowledge about a link between respective deiodinase 
type 1 and 3 and the status of thyroid hormones. We did 
not exclude the influence of DIO1 and DIO3 as important 
modulators of TH levels and their impact on the func‑
tion of the brain, particularly since there is evidence for 
the interaction between TH and the neurotransmitter 
involved in the development and course of depression 
(Bauer et al., 2008). From the point of view of research 
and a scientific discussion, no clear information is pro‑
vided whether an increase or a decrease in T3 and/or T4 
levels is associated with the risk of depression. Both low 
and high levels of T3 and T4 can be related to depressive 
disorders (Premachandra et al. 2006, Bauer 2008), yet 
changes in the thyroid hormone are not very common 
(Fava et al. 1995). 
The main aim of the study was to investigate the lev‑
els of DIO1 and DIO3 in the patients who were diagnosed 
with rDD. We would like to explain that we decided to 
investigate DIO1 and DIO3 because these molecules are 
related to inflammatory processes and are known to be 
immune players. Certain reports indicate a correlation 
between DIO1 and DIO3 and inflammation and bacteri‑
al infections (Pappa et al. 2011,Wajner and Maia 2012, 
van der Spek et al. 2016). The possible mechanism ex‑
plaining the role of DIO 3 is the fact that the enzyme is 
a source of iodide, which together with hydrogen perox‑
ide is utilized by myeloperoxidase (MPO). As a result of 
such a reaction, hypoiodite is created, i.e. a toxic com‑
pound that can kill bacteria (Klebanoff 1967, Boelen et 
al. 2011). It is also worth emphasizing that DIO3 has been 
recently found in human neutrophils in the intracellular 
granules participating in the process of bacteria elimi‑
nation (van der Spek et al. 2016). There is much less in‑
formation regarding DIO1; nevertheless, the expression 
of this molecule is also present in human neutrophils 
(van der Spek et al., 2016). We decided to focus on DIO1 
and DIO3 because depressive disorders are characterized 
by an inflammation, immune cells activation, a high‑
er level of proinflammatory cytokines (Anisman 2009), 
and increased expression of MPO (Gałecki et al. 2012); 
moreover, lipopolysaccharides are capable of inducing 
depressive‑like behavior (Maes et al. 2008).
The data recorded by us may be of importance in 
the inflammatory theory of cytokine‑induced depres‑
sion, as many inflammation markers, including proin‑
flammatory cytokines, affect gene expression for the 
enzymes mentioned above. In our opinion, the results 
may serve to confirm that different multidirection‑
al molecules can participate in the immuno‑inflam‑
matory mechanism of depression. The results may be 
considered an introduction to a discussion about the 
participation of the investigated deiodinases in the eti‑
ology of depression.
CONCLUSION
Our study is the first to present that peripheral DIO1 
and DIO3 expression on mRNA/protein levels may be as‑
sociated with depressive disorders, while deiodinase‑re‑
lated mechanisms may participate in the development 
and course of the disease. Further investigations of DIO1 
and DIO3 levels on a more diverse population of patients 
are required to explore the complex role of the mole‑
cules and examine the changes of expression during de‑
pression‑related pathologic mechanisms.
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